Botulinum toxins in the treatment of migraine and tension-type headaches

Physical Medicine and Rehabilitation Clinics of North America

Volumn 14, Issue 4, 2003, Pages 885-899

  Winner, Paul ^a,b  

^a Palm Beach Headache Center   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCIUM CHANNEL BLOCKING AGENT; DEPAKOTE ER; METHYSERGIDE MALEATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPRANOLOL; TIMOLOL MALEATE; VALPROATE SEMISODIUM;

HUMAN; INJECTION PAIN; MIGRAINE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; PAIN; PRIORITY JOURNAL; PTOSIS; REVIEW; SIDE EFFECT; SPASTICITY; TENSION HEADACHE; TREATMENT INDICATION;

EID: 0141954148     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-9651(03)00094-9     Document Type: Review

References (25)

1. Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2001;2:1649-54.
2. Allergan's Botox cosmetic approval by the FDA for the treatment of glabellar lines. Available at: http://www.botox.com/pages/glabellar_popup.jsp Accessed July 16, 2002.
3. Silberstein SD, Mathew N, Saper JS, et al. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-50.
4. Stewart W, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9.
5. Lipton RB, Stewart WF, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States. Data from the American Migraine Study II. Headache 2001;41:646-57.
6. Stewart W, Shechter A, Rasmussen RK. Migraine prevalence. A review of population-based studies. Neurology 1994;44(Suppl 14):517-23.
7. Winner P, Linder S, Wasiewski W. Pharmacologic treatment of headache: headache in children and adolescents. Hamilton (Ontario, Canada): BC Decker; 2001.
8. Thomson PDR. Botox (botulinum toxin type A) purified neurotoxin complex. In: Physicians' desk reference. 57th edition. Montvale (NJ); 2003. p. 1263-5
9. Thomson PDR. Myobloc (botulinum toxin type B) injectable solution. In: Physicians' desk reference. 57th edition. Montvale (NJ); 2003. p. 1263-5.
10. Binder WJ, Brin MF, Blitzer A, Pogoda JM. Botulinum toxin type A for treatment of migraine. Semin Cutan Med Surg 2001;20:93-100.
11. Brin MF, Swope DM, Abassi S, et al. Botulinum toxin type A for migraine: double-blind, placebo controlled region specific evaluation. Poster presented at the Headache World 2000, London, September 2000 (poster 1196).
12. Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A in the prophylactic treatment of migraine. Presented at the American Headache Society 44th Annual Scientific Meeting, Seattle, Washington, June 21-23, 2002.
13. Eross EG, Dodick DW. The effects of botulinum toxin type A on disability in episodic and chronic miraine. Presented at the American Headache Society 44th Annual Scientific Meeting, Seattle, Washington, June 21-23, 2002 [abstract S108].
14. Relja M, Zagreb KN, et al. Botulinum toxin type A reduces acute medication (triptans) use in migraine patients. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.147).
15. Lake A, Saper J. Botulinum toxin type B for migraine prophylaxis: a 4-month open-label prospective outcome study. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.150).
16. Mathew N, Kallasam J, Kaupp A, et al. "Disease modification" in chronic migraine with botulinum toxin type A: long-term experience. Presented at the American Headache Society 44th Annual Scientific Meeting, Seattle, Washington, June 21-23, 2002.
17. Schmitt WJ, Fravin SE, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41:658-64.
18. Rollnik JD, Karst M, Fink M, et al. Botulinum Toxin type A and EMG: a Key to the Understanding of Chronic Tension-type headache? Headache 2001;41:985-9.
19. de Brujin SFTM, Padberg M, Tavy DLJ. Treatment of chronic tension-type headache with botulinum toxin: a double blind placebo-controlled clinical trial. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.152).
20. Blumenfeld A. Botulinum toxin type A as an effecfive preventive treatment in headache. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.152).
21. Gwynn MW, Baker T, English J. Botulinum toxin type A as an effective preventive treatment in headache. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.149).
22. Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM. Botulinum toxin A in the preventive treatment of refractory headache. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.151).
23. Troost T, Rosenberg JR. Improvement in intractable headache with repeated botulinum toxin type A treatment. Presented at the American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2, 2003 (abstract PO4.153).
24. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A (Botox) in a combination fixed-injection-site and "follow the pain" protocol. Presented at the American Headache Society 44th Annual Scientific Meeting, Seattle, Washington, June 21-23, 2002 (abstract S138).
25. Miller T, Denny L. Retrospective cohort analysis of 48 chronic headache patients treated with botulinum toxin type A (Botox) in a combination fixed injection site and "follow the pain" protocol. Presented at the American Headache Society 44th Annual Scientific Meeting, Seattle, Washington, June 21-23, 2002 (abstract S138).